MediciNova, Inc. (MNOV)
| Previous close | 2.3100 |
| Open | 2.3200 |
| Bid | 2.1500 x 800 |
| Ask | 2.4300 x 900 |
| Day's range | 2.3200 - 2.4200 |
| 52-week range | 2.0900 - 5.0900 |
| Volume | |
| Avg. volume | 48,745 |
| Market cap | 117.704M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2320 |
| Earnings date | 16 Feb 2022 - 21 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1,100.00 |
- Simply Wall St.
We're Not Very Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GlobeNewswire
MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference
LA JOLLA, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will participate in a fireside chat, hosted by B. Riley Analyst Mayank Mamtani, regarding MediciNova’s development of MN-166 (ibud
- GlobeNewswire
MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research
LA JOLLA, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced data demonstrating that MN-166 (ibudilast) prevents metastasis in a uveal melanoma (UM) animal model was published in the journal Molecular Cancer Research. The publication entitled “Uveal Melanoma Exosomes Induce a Prometastatic Microenvironment through Macrophage
